EN DE
Watch MEDIANA Co.Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MEDIANA Co.Ltd (041920) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of MEDIANA Co.Ltd stock KRW 5,424, price KRW 6,730, that is 19.4% below the price, quality 58 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7041920000

MC MEDIANA Co.Ltd logo Some data Nov 8, 2026

MEDIANA Co.Ltd

041920 · KQ
Solid, but expensive

Our calculation puts a fair price 19% below what the stock costs today.

Highly profitable · 21.9% net margin (TTM)
Low debt
Generates free cash flow
Ranks above peers (11/13)
Revenue last quarter +60% vs. a year ago.
Quality 58/100
Wide moat 68/100 · thin data
Some data
Fair value 5,424 KRW · Overvalued
Weak Growth (revenue 5y −0.8 %/yr in KRW)
Watch MEDIANA Co.Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

28,650 KRW 3,733 KRW Fair Value 5,424 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 3,733 KRW – 28,650 KRW · fair‑value band 4,029 KRW – 7,312 KRW · the 6,730 KRW price screens above the 5,424 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow MEDIANA Co.Ltd in your weekly email

Every Wednesday you see whether MEDIANA Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mediana Co.,Ltd, together with its subsidiaries, develops, manufactures, and sells medical devices in South Korea.

Show moreShow less

It offers patient monitors, vital signs monitors, AEDs, monitors/defibrillators, fetal products, body composition analyzers, central monitoring systems, face masks, spot checks and monitors, pulse oximeters, and physio modules.

The company also exports ODM and own branded products through agencies in approximately 80 countries. Mediana Co.,Ltd was founded in 1993 and is headquartered in Wonju-si, South Korea.

Stock analysis

MEDIANA Co.Ltd (041920) currently trades at 6,730 KRW, while our model-based Fair Value estimate is 5,424 KRW, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 6,616 KRW per share, and 4 of the 26 models we run sit above the 6,730 KRW price.

Bear case: the Earnings-Based group reads lowest at 2,650 KRW, and 22 of the 26 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 4,029 KRW (bear) to 7,312 KRW (bull), the price of 6,730 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

MEDIANA Co.Ltd reported revenue of 64.9B KRW in FY2025 versus 56.8B KRW in FY2021, a compound +3.4%/yr. Reported net income was 5.3B KRW in FY2025, compounding −11.9%/yr from FY2021.

Key figures

Market cap 150B KRW (≈ $111M) Micro · P/S ratio 2.31 · Dividend yield 0.3% · Net margin 21.9% · Return on equity 395% · Return on assets (EBIT) 6.6% (5-year average) · Operating margin 15.6% · Revenue (TTM) 65.0B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at −19%, 041920 screens richer than that median.

Fair Value models

Bear 4,029 KRW Fair Value 5,424 KRW Bull 7,312 KRW
Price 6,730 KRW · Downside -19.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 3,596 KRW 4,432 KRW 5,471 KRW 81
Growth DCF 3,591 KRW 4,304 KRW 5,133 KRW 79
Owner Earnings 2,901 KRW 3,466 KRW 4,167 KRW 77
All 26 models by family
DCF Models
FCF DCF 3,596 KRW 4,432 KRW 5,471 KRW 81
Owner Earnings 2,901 KRW 3,466 KRW 4,167 KRW 77
5Y Revenue Exit 3,947 KRW 5,424 KRW 7,312 KRW 72
5Y EBITDA Exit 4,464 KRW 6,401 KRW 8,672 KRW 75
5Y P/E Exit 4,713 KRW 6,870 KRW 9,153 KRW 70
10Y Revenue Exit 3,690 KRW 4,849 KRW 6,408 KRW 67
10Y EBITDA Exit 4,029 KRW 5,416 KRW 7,277 KRW 68
10Y P/E Exit 4,161 KRW 5,687 KRW 7,585 KRW 64
Earnings-Based
Graham-Dodd 1,944 KRW 6,401 KRW 8,559 KRW 62
Lynch FV 1,441 KRW 2,058 KRW 2,676 KRW 58
PEG = 1.0 1,441 KRW 2,058 KRW 2,676 KRW 55
EPV 3,059 KRW 3,242 KRW 3,389 KRW 72
Dividend Discount
Gordon GGM 144.27 KRW 235.56 KRW 300.06 KRW 66
DDM Multi-Stage 144.27 KRW 219.37 KRW 253.96 KRW 65
Multiples
P/E Multiple 4,717 KRW 6,289 KRW 7,861 KRW 61
P/S Multiple 3,645 KRW 4,860 KRW 6,075 KRW 56
P/B Multiple 6,876 KRW 9,168 KRW 11,460 KRW 53
EV/EBIT 5,572 KRW 6,942 KRW 8,313 KRW 65
EV/EBITDA 5,667 KRW 7,069 KRW 8,472 KRW 66
EV/Revenue 4,395 KRW 5,652 KRW 6,910 KRW 53
Asset-Based
NCAV (Graham) 3,628 KRW 5,498 KRW 6,872 KRW 53
Growth DCF
Growth DCF 3,591 KRW 4,304 KRW 5,133 KRW 79
Rev-Margin DCF 3,947 KRW 5,425 KRW 7,147 KRW 73
Economic Profit
Residual Income 4,369 KRW 4,446 KRW 4,801 KRW 75
ROIC Compounder 3,059 KRW 3,242 KRW 3,389 KRW 71
Growth Earnings
Growth-Adj P/E 3,958 KRW 5,654 KRW 7,350 KRW 66

Open the full fair value analysis →

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 52
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 55
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 37
Distance to the 52-week high, does not count
New shares 56
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+13.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Start year 2020 (pandemic). Over 10 years: +3.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−12.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.3%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12.3% vs −5.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −4.5% a year for the price.

041920 screens overvalued: fair value 19% below the price. Compare with InBody Co →

Compare MEDIANA Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2276 stocks

Beats the sector median on 10/12 measures
Overall it ranks above its sector peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −19.4% · Above median
Profitability
Return on equity (12 months) 395.5% · Top 25%
Return on assets 3.6% · Above median
Net margin (12 months) 21.9% · Top 25%
Operating margin (12 months) 15.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 59.8% · Top 25%
Dividend yield (12 months) 0.3% · Bottom 25%

Valuation Multiplesvs Health Care median · lower = cheaper

P/B 1.11× · Cheaper than median
P/S (12 months) 2.31× · Cheaper than median
Price / free cash flow (fiscal year) 30.6× · Pricier than median
EV/EBITDA 10.3× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 5
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)100 · sector 18
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)5 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Value Added Technology Co 043150 16,640 KRW 48,636 KRW +192% vs 041920
Sewoon Medical Co 100700 2,255 KRW 5,541 KRW +146% vs 041920
Meta Biomed Co 059210 3,320 KRW 6,997 KRW +111% vs 041920
MEKICS CO., Ltd 058110 1,283 KRW 1,581 KRW +23% vs 041920
InBody Co 041830 42,050 KRW 49,984 KRW +19% vs 041920
AbbVie Inc ABBV $291.31 $259.62 −11% vs 041920
Merck & Co MRK $146.73 $129.26 −12% vs 041920
Roche Holding RO CHF 400.00 CHF 326.56 −18% vs 041920
Johnson & Johnson, JNJ $276.22 $168.85 −39% vs 041920
Eli Lilly and Company LLY $1,354 $749.92 −45% vs 041920

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MEDIANA Co.Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MEDIANA Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/041920

Frequently asked questions

Is MEDIANA Co.Ltd (041920) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 5,424 KRW versus a price of 6,730 KRW, about 19% lower (overvalued).
What is the fair value of 041920?
Our model-based fair value for MEDIANA Co.Ltd is 5,424 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 6,730 KRW.
What is the quality score of 041920?
MEDIANA Co.Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEDIANA Co.Ltd (041920)?
Our model-based price target is the fair value of 5,424 KRW (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 4,029 KRW, optimistic scenario 7,312 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the MEDIANA Co.Ltd stock forecast for 2026?
Our models put fair value at 5,424 KRW, about 19% lower versus a price of 6,730 KRW (overvalued). Cautious scenario 4,029 KRW, optimistic scenario 7,312 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MEDIANA Co.Ltd (041920)?
MEDIANA Co.Ltd reported trailing-twelve-month revenue of about 65.0B KRW (latest available figure, as of Nov 8, 2026).
Does MEDIANA Co.Ltd pay a dividend?
MEDIANA Co.Ltd currently shows a dividend yield of 0.27% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of MEDIANA Co.Ltd (041920)?
MEDIANA Co.Ltd has a dividend yield of 0.3%.
What growth is priced into MEDIANA Co.Ltd (041920)?
For today's price to be fair in a discounted-cash-flow model, MEDIANA Co.Ltd would have to grow free cash flow by -2.6 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.8 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 041920 use?
Our models discount MEDIANA Co.Ltd at 13.1 %: a base by market capitalisation (micro), country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MEDIANA Co.Ltd that is -2.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has MEDIANA Co.Ltd (041920) delivered so far?
Over the past 5 years revenue at MEDIANA Co.Ltd grew -0.8 % a year. The price currently implies free-cash-flow growth of -2.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MEDIANA Co.Ltd (041920) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into MEDIANA Co.Ltd (-2.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MEDIANA Co.Ltd (041920)?
The free-cash-flow yield on the price is 3.94 %: that much free cash flow MEDIANA Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MEDIANA Co.Ltd (041920)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEDIANA Co.Ltd it is 5,424 KRW per share (as of Nov 8, 2026), against a price of 6,730 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is MEDIANA Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 041920 trades above its calculated fair value: price 6,730 KRW, fair value 5,424 KRW, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 041920?
No. The price is what the market pays today (6,730 KRW); the fair value is what the company's own numbers justify (5,424 KRW). For MEDIANA Co.Ltd the two are 1,306 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MEDIANA Co.Ltd worth?
The market values MEDIANA Co.Ltd at about 150B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 6,730 KRW; our models calculate a fair value of 5,424 KRW per share.
What do the bullish and bearish scenarios say about 041920?
Our models span a range for MEDIANA Co.Ltd: cautious scenario 4,029 KRW, base 5,424 KRW, optimistic 7,312 KRW per share (as of Nov 8, 2026, price 6,730 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MEDIANA Co.Ltd (041920)?
Balance-sheet figures for MEDIANA Co.Ltd (as of Nov 8, 2026): return on equity 395.5%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 041920 from its 52-week high?
MEDIANA Co.Ltd trades at 6,730 KRW, about 77% below its 52-week high of 28,650 KRW and 29% above the low of 5,210 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 5,424 KRW is for.
Which stocks are comparable to MEDIANA Co.Ltd?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Sewoon Medical Co, Meta Biomed Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEDIANA Co.Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 6,730 KRW, calculated fair value 5,424 KRW (−19%), Quality Score 58/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 041920 calculated?
We run MEDIANA Co.Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5,424 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. MEDIANA Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEDIANA Co.Ltd (041920)?
The closing price on Nov 6, 2026 was 6,730 KRW. Our model-based fair value is 5,424 KRW, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEDIANA Co.Ltd right now?
Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (4,029 KRW to 7,312 KRW) leaves room in how you read the outcome.

Key figures of MEDIANA Co.Ltd

How large is the market capitalisation of MEDIANA Co.Ltd (041920)?
The market capitalisation of MEDIANA Co.Ltd is 150B KRW (≈ $111M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEDIANA Co.Ltd (041920)?
The price-to-sales ratio of MEDIANA Co.Ltd is 2.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of MEDIANA Co.Ltd (041920)?
The dividend yield of MEDIANA Co.Ltd is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of MEDIANA Co.Ltd (041920)?
The net margin of MEDIANA Co.Ltd is 21.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEDIANA Co.Ltd (041920)?
The return on equity (ROE) of MEDIANA Co.Ltd is 395% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEDIANA Co.Ltd (041920)?
On an EBIT basis the return on assets of MEDIANA Co.Ltd is 6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEDIANA Co.Ltd (041920)?
The operating margin of MEDIANA Co.Ltd is 15.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEDIANA Co.Ltd (041920)?
Revenue at MEDIANA Co.Ltd is growing +59.8% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEDIANA Co.Ltd (041920)?
Earnings per share at MEDIANA Co.Ltd are growing +202% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch MEDIANA Co.Ltd in the live analysis

One click puts MEDIANA Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.